Catalyst Pharmaceuticals (CPRX) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.28% |
| Dec 31, 2025 | 27.92% |
| Sep 30, 2025 | 23.15% |
| Jun 30, 2025 | 39.98% |
| Mar 31, 2025 | 52.78% |
| Dec 31, 2024 | 41.96% |
| Sep 30, 2024 | 34.98% |
| Jun 30, 2024 | 35.44% |
| Mar 31, 2024 | 43.01% |
| Dec 31, 2023 | 54.01% |
| Sep 30, 2023 | 53.39% |
| Jun 30, 2023 | 53.27% |
| Mar 31, 2023 | 31.85% |
| Dec 31, 2022 | 64.22% |
| Sep 30, 2022 | 77.64% |
| Jun 30, 2022 | 59.06% |
| Mar 31, 2022 | 33.15% |
| Dec 31, 2021 | 44.71% |
| Sep 30, 2021 | 53.86% |
| Jun 30, 2021 | 41.18% |
| Mar 31, 2021 | 21.46% |
| Dec 31, 2020 | 37.02% |
| Sep 30, 2020 | 32.88% |
| Jun 30, 2020 | 38.65% |
| Mar 31, 2020 | 31.29% |
| Dec 31, 2019 | 38.46% |
| Sep 30, 2019 | 45.75% |
| Jun 30, 2019 | 46.36% |
| Mar 31, 2019 | -27.01% |
| Dec 31, 2018 | -15.12% |
| Sep 30, 2018 | -32.79% |
| Jun 30, 2018 | -21.31% |
| Mar 31, 2018 | -22.01% |
| Dec 31, 2017 | -20.38% |
| Sep 30, 2017 | -19.05% |
| Jun 30, 2017 | -22.84% |
| Mar 31, 2017 | -24.41% |
| Dec 31, 2016 | -25.13% |
| Sep 30, 2016 | -21.22% |
| Jun 30, 2016 | -24.31% |
| Mar 31, 2016 | -48.14% |
| Dec 31, 2015 | -43.20% |
| Sep 30, 2015 | -45.57% |